Compare · MGRX vs PGNY
MGRX vs PGNY
Side-by-side comparison of Mangoceuticals Inc. (MGRX) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MGRX and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- PGNY is the larger of the two at $2.08B, about 250.2x MGRX ($8.3M).
- Over the past year, MGRX is down 81.7% and PGNY is up 19.0% - PGNY leads by 100.8 points.
- PGNY has been more active in the news (7 items in the past 4 weeks vs 1 for MGRX).
- PGNY has more recent analyst coverage (25 ratings vs 0 for MGRX).
- Company
- Mangoceuticals Inc.
- Progyny Inc.
- Price
- $0.39-4.82%
- $27.56+1.79%
- Market cap
- $8.3M
- $2.08B
- 1M return
- -27.70%
- +8.50%
- 1Y return
- -81.74%
- +19.05%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- 2019
- News (4w)
- 1
- 7
- Recent ratings
- 0
- 25
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest MGRX
- Mangoceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 10-Q filed by Mangoceuticals Inc.
- SEC Form 425 filed by Mangoceuticals Inc.
- Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets
- Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets
- Nuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
- Mangoceuticals’ Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
- Nuclea Energy USA Inc. Announces MOU with Utah Office of Energy Development
- Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development
- SEC Form 425 filed by Mangoceuticals Inc.
Latest PGNY
- SEC Form 144 filed by Progyny Inc.
- CHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 5,361 shares, decreasing direct ownership by 0.66% to 806,111 units (SEC Form 4) to satisfy tax liability
- EVP, GC Swartz Allison covered exercise/tax liability with 1,307 shares, decreasing direct ownership by 2% to 79,719 units (SEC Form 4) (withholding tax)
- CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 479 shares, decreasing direct ownership by 0.66% to 72,453 units (SEC Form 4) (withholding tax)
- Progyny, Inc. to Present at the Wells Fargo Healthcare Conference
- EVP, GC Swartz Allison covered exercise/tax liability with 1,352 shares, decreasing direct ownership by 2% to 81,026 units (SEC Form 4) to satisfy withholding tax
- Wells Fargo initiated coverage on Progyny with a new price target
- Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
- SEC Form 10-Q filed by Progyny Inc.
- Progyny Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits